Compare Lithium Americas Corp (LAC) vs Mesoblast Limited (MESO) Price & Performance

Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.

LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.